晚期卵巢癌新辅助化疗与传统化疗近期临床疗效的系统评价

摘要

目的 系统评价晚期卵巢癌新辅助化疗的临床疗效.方法 计算机检索PubMed、CENTRAL、EMbase、The ISI Web of Knowledge databases、VIP、CNKI、CBM 和WANFANG 数据库,查找所有比较新辅助化疗(NACT)与传统化疗(ACT)治疗晚期卵巢癌疗效的RCT,检索时限为2005年1月~2011年12月,按纳入排除标准由两人依据Cochrane Handbook 5.0.1的质量评价标准独立进行RCT筛选、资料提取和质量评价后,按Cochrane协作网推荐的方法使用RevMan5.0软件对相关病例对照研究进行Meta分析.结果 共纳入6项随机对照研究,共472例患者.Meta分析结果显示:NACT相比于ACT在术后3年生存率、并发症发生率方面差异无统计学意义(P ＞ 0.05),与ACT相比,NACT有更高的手术最佳减免率和术后一年生存率(P ＜ 0.05).结论 新辅助化疗适用于某些晚期卵巢癌,可提高外科治疗效果,并有延长患者生存时间的趋势.%Objective To systematically evaluate the curative effect of new adjuvant chemotherapy for the treatment of advanced ovarian cancer. Methods The databases such as PubMed, CENTRAL, Embase, VIP, CNKI, CBM and Wanfang Data were searched to collect all randomized control trials (RCTs) about the curative effect of new adjuvant chemotherapy for the treatment of advanced ovarian cancer. The time limit was from January 2005 to December 2011.Literatures were screened according to the inclusive and exclusive criteria by two people independently, the data were extracted, the methodological quality of the included studies was assessed in line with Cochrane Handbook 5.0.1. Meta-analysis was conducted with RevMan5 software using the methods recommended by the Cochrane Collaboration. Results Six RCTs involving 472 patients were included. Meta analysis results showed that NACT compared to ACT in the three years of survival rate, complications rate had no statistically significant differences (P > 0.05), compared with the ACT, NACT had higher operation best reduction rate and postoperative year survival rate (P < 0.05). Conclusion New adjuvant chemotherapy can improve the surgical treatment effect and prolong survival time trend for some advanced ovarian cancer.